Aligos’ licensing deal in China broadens trial scope, secures immediate $25m
By Steve Scherer ( April 28, 2026, 20:42 GMT | Insight) -- Aligos Therapeutics’ recent China licensing deal for chronic hepatitis B therapies enables it to broaden clinical development, generate more data, and tap into the world’s largest market for these treatments.Aligos Therapeutics’ recent agreement to license and develop treatments for chronic hepatitis B in China allows the company to expand clinical development and data generation and gain access to the world’s biggest market for such treatments....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.